Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT02864992
Active, not recruiting Phase 2

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992 · tracked via the Priya Life Science Italy tracker
Sponsor
EMD Serono Research & Development Institute, Inc
Phase
Phase 2
Started
2016-09-13
Last updated
2026-07-14

Condition(s) studied

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV

Investigational drug(s) / intervention(s)

Tepotinib →

Tepotinib: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Study summary

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Signed, written informed consent by participant or legal representative prior to any trial-specific screening procedure * Male or female, greater than or equal to (\>=) 18 years of age (or have reached the age of majority according to local laws and regulations) * Measurable disease confirmed by an independent review committee (IRC) in accordance with RECIST version 1.1 * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 * A female participant was eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential OR * A woman of childbearing potential who agrees to use a highly effective contraception * A male participant must agree to use and to have their female partners of childbearing potential to use a highly effective contraception * Histologically or cytologically confirmed advanced (locally advanced or metastatic) NSCLC (all types including squamous and sarcomatoid) * Treatment naïve participant in first-line or pretreated participant with no more than 2 lines of prior therapy * Participants with MET alterations, namely METex14 skipping alterations in plasma and/or tissue as determined by the central laboratory or by an assay with appropriate regulatory status Exclusion Criteria: * Participants with characterized Epidermal Growth Factor Receptor (EGFR) activating mutations that predict sensitivity to anti-EGFR-therapy * Participants with characterized Anaplastic Lymphoma Kinase (ALK) rearrangements that predict sensitivity to anti-ALK therapy * Participants with symptomatic brain metastases who are neurologically unstable * Any unresolved toxicity Grade 2 or more according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) from previous anticancer therapy * Need for transfusion within 14 days prior to the first dose of trial treatment * Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of trial treatment; * Participants who have brain metastasis as the only measurable lesion * Inadequate hematological, liver, renal, cardiac function * Prior treatment with other agents targeting the Hepatocyte Growth Factor c(HGF/c) -Met pathway * Hypertension uncontrolled by standard therapies (not stabilized to \< 150/90 mmHg) * Past or current history of neoplasm other than Non-small Cell Lung Cancer (NSCLC), except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years * Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the test product * Major surgery within 28 days prior to Day 1 of trial treatment * Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C virus * Substance abuse, active infection, or other acute or chronic medical or psychiatric condition or laboratory abnormalities that might increase the risk associated with trial participation at the discretion of Investigators * Known hypersensitivity to any of the trial treatment ingredients * Legal incapacity or limited legal capacity * Any other reason that, in the opinion of the Principal Investigator, precludes the participant from participating in the trial * Participation in another clinical trial within the past 30 days

Primary outcome measure(s)

  • Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC) — Time from first treatment up to data cutoff (approximately Month 66)
    Objective response will be determined according to RECIST 1.1 and as per IRC. Objective response was defined as number of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
  • Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC) — Time from first treatment up to data cutoff (approximately Month 66)
    Objective response will be determined according to RECIST 1.1 and as per IRC. Objective response was defined as number of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
  • Part 2: Cohort C: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC) — Time from first treatment up to data cutoff (approximately Month 66)
    Objective response will be determined according to RECIST 1.1 and as per IRC. Objective response was defined as number of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Trial sites (176)

FacilityCityRegionStatus
City of Hope Cancer Center Duarte California
California Cancer Associates for Research & Excellence, Inc. Encinitas California
St. Joseph Hospital Orange California
Torrance Health Association Redondo Beach California
St Joseph Heritage Healthcare Santa Rosa California
Rocky Mountain Cancer Centers, LLP Denver Colorado
Holy Cross Hospital Inc. Fort Lauderdale Florida
H. Lee Moffitt Cancer Center and Research Institute, Inc Tampa Florida
University Cancer & Blood Center, LLC Athens Georgia
Winship Cancer Institute Atlanta Georgia
University of Chicago Medical Center Chicago Illinois
Ingalls Hospital Harvey Illinois
Community Regional Cancer Care Indianapolis Indiana
Center for Cancer and Blood Disorders Bethesda Maryland
For Recruiting Locations in the United States, please Contact U.S. Medical Information Rockland Massachusetts
St. Louis Cancer Care, LLP Bridgeton Missouri
Saint Louis University Cancer Center St Louis Missouri
Saint Louis University St Louis Missouri
Summit Medical Group, P.A. Berkeley Heights New Jersey
Summit Medical Group Berkeley Heights New Jersey
Regional Cancer Care Associates East Brunswick East Brunswick New Jersey
Somerset Hematology Oncology Associates - Somerville Location East Brunswick New Jersey
Hackensack University Medical Center PARTNER Hackensack New Jersey
Prospect Medical Offices, LLC Midland Park New Jersey
The Valley Hospital Ridgewood New Jersey
Memorial Sloan Kettering Cancer Center - Commack Commack New York
Memorial Sloan Kettering Cancer Center, West Harrison Regional Outpatient Pavilion Harrison New York
Memorial Sloan Kettering Cancer Center New York New York
UC Health Clinical Trials Office Cincinnati Ohio
University of Cincinnati - PARENT Cincinnati Ohio
Tennessee Oncology Nashville Tennessee
Vanderbilt University Medical Center Nashville Tennessee
Texas Oncology, P.A. - Austin Austin Texas
Texas Oncology, PA Beaumont Texas
University of Texas MD Anderson Cancer Center Houston Texas
Virginia Cancer Specialists, PC Fairfax Virginia
Swedish Medical Center Seattle Washington
Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson Wenatchee Washington
Wenatchee Valley Medical Center Oncology Wenatchee Washington
LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie Salzburg Austria

+ 136 more sites — see the full list on the official registry below.

More EMD Serono Research & Development Institute, Inc. trials in Italy

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease Recruiting
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Active, not recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02864992 on ClinicalTrials.gov ↗ ← All trials in Italy